News-Medical.Net July 29, 2024
Hugo Francisco de Souza

In a recent review published in the journal Obesity Pillars, a team of researchers collate and narratively review the literature on the dietary impacts of obesity or type 2 diabetes (T2D) patients undergoing glucagon-like peptide receptor agonists (GLP-1RAs) or glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) clinical interventions.

Their findings highlight a significant shortage of available information, with only a limited amount of previously published studies meeting their review inclusion criteria. Furthermore, while these interventions achieve notable reductions in total caloric intakes (16-39%), dietary composition is rarely scientifically evaluated in receptor agonist studies. The authors recommend future studies to assess the protein and essential micronutrient intake change following GLP-1 or GIP/GLP-1 interventions and include a registered dietitian nutritionist (RDN) in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article